Mostrar el registro sencillo del ítem

dc.contributor.author
Rozenblum, Tomas Guido  
dc.contributor.author
Lopez, Vanina Gisela  
dc.contributor.author
Vitullo, Alfredo Daniel  
dc.contributor.author
Radrizzani Helguera, Martin  
dc.date.available
2018-04-24T17:35:25Z  
dc.date.issued
2015-12  
dc.identifier.citation
Rozenblum, Tomas Guido; Lopez, Vanina Gisela; Vitullo, Alfredo Daniel; Radrizzani Helguera, Martin; Aptamers: current challenges and future prospects; Informa Healthcare; Expert Opinion On Drug Discovery; 11; 2; 12-2015; 127-135  
dc.identifier.issn
1746-0441  
dc.identifier.uri
http://hdl.handle.net/11336/43257  
dc.description.abstract
Introduction: Aptamers are oligonucleotide molecules raised in vitro from large combinatorial libraries of nucleic acids and developed to bind to targets with high affinity and specificity. Whereas novel target molecules are proposed for therapeutic intervention and diagnostic, aptamer technology has a great potential to become a source of lead compounds.Areas Covered: In this review the authors address the current status of the technology and highlight the recent progress in aptamer-based technologies. They also discuss the current major technical limitations of aptamer technology and propose original solutions based on existing technologies that could result in a solid aptamer-discovery platform.Expert opinion: Whereas aptamers have shown to bind to targets with similar affinities and specificities to those of antibodies, aptamers have several advantages that could outweigh antibody technology and open new opportunities for better medical and diagnostic solutions. However, the current status of the aptamer technology suffers from several technical limitations that slowdown the progression of novel aptamers into the clinic and makes the business around aptamers challenging.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Informa Healthcare  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Aptamer  
dc.subject
Biosensors  
dc.subject
Lead Discovery  
dc.subject
Dna Array  
dc.subject.classification
Otras Biotecnologías de la Salud  
dc.subject.classification
Biotecnología de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Aptamers: current challenges and future prospects  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-04-17T13:49:07Z  
dc.journal.volume
11  
dc.journal.number
2  
dc.journal.pagination
127-135  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Rozenblum, Tomas Guido. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Maimónides; Argentina  
dc.description.fil
Fil: Lopez, Vanina Gisela. Universidad Maimónides; Argentina  
dc.description.fil
Fil: Vitullo, Alfredo Daniel. Universidad Maimónides; Argentina  
dc.description.fil
Fil: Radrizzani Helguera, Martin. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín; Argentina  
dc.journal.title
Expert Opinion On Drug Discovery  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1517/17460441.2016.1126244  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/17460441.2016.1126244